Last update 04 Jun 2026

HRS-6208

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
HRS-6208
Target
CDK7
Action
inhibitors
Mechanism
CDK7 inhibitors(Cyclin-dependent kinase 7 inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Advanced breast cancerAdvanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Shandong Suncadia Medicine Co., Ltd.
Active Organization
Shandong Suncadia Medicine Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with HRS-6208
NCT07389733
/ RecruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-6208 in Combination With HRS-8080 ± HRS-6209, or in Combination With Fulvestrant ± HRS-6209, or in Combination With Letrozole ± HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: an Open Label, Multicenter, Phase Ib/II Study
NCT06727812
/ RecruitingPhase 1
A Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-6208 Monotherapy in Patients With Advanced Solid Tumors
ChiCTR2400093413
/ Not yet recruitingPhase 1IIT
A Phase I Clinical Study of the Safety,Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6208 Monotherapy in Patients With Advanced Solid Tumors
100 Clinical Results associated with HRS-6208
Login to view more data
100 Translational Medicine associated with HRS-6208
Login to view more data
100 Patents (Medical) associated with HRS-6208
Login to view more data
100 Deals associated with HRS-6208
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 2
China
Shandong Suncadia Medicine Co., Ltd.
19 Mar 2026
Advanced breast cancerPhase 2
China
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
19 Mar 2026
Advanced Malignant Solid NeoplasmPhase 1
China
-09 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free